Algert Global LLC grew its position in Phibro Animal Health Corp (NASDAQ:PAHC) by 37.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,385 shares of the company’s stock after acquiring an additional 7,800 shares during the period. Algert Global LLC owned about 0.07% of Phibro Animal Health worth $1,218,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of PAHC. Laurion Capital Management LP purchased a new stake in Phibro Animal Health in the third quarter valued at approximately $411,000. Renaissance Technologies LLC grew its holdings in Phibro Animal Health by 26.7% in the third quarter. Renaissance Technologies LLC now owns 803,800 shares of the company’s stock valued at $34,483,000 after purchasing an additional 169,300 shares during the period. GSA Capital Partners LLP grew its holdings in Phibro Animal Health by 12.3% in the third quarter. GSA Capital Partners LLP now owns 28,015 shares of the company’s stock valued at $1,202,000 after purchasing an additional 3,067 shares during the period. Fuller & Thaler Asset Management Inc. grew its holdings in Phibro Animal Health by 12.6% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 390,489 shares of the company’s stock valued at $16,752,000 after purchasing an additional 43,825 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Phibro Animal Health by 1.7% in the third quarter. Dimensional Fund Advisors LP now owns 511,279 shares of the company’s stock valued at $21,933,000 after purchasing an additional 8,754 shares during the period. 49.63% of the stock is currently owned by institutional investors and hedge funds.
In other news, VP Daniel M. Bendheim sold 2,500 shares of the business’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $44.30, for a total transaction of $110,750.00. Following the transaction, the vice president now directly owns 2,500 shares of the company’s stock, valued at $110,750. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dean J. Warras sold 10,000 shares of the business’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $42.84, for a total transaction of $428,400.00. Following the transaction, the insider now directly owns 10,000 shares in the company, valued at $428,400. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,020 shares of company stock worth $562,571. Corporate insiders own 50.29% of the company’s stock.
PAHC opened at $32.87 on Friday. The company has a quick ratio of 1.82, a current ratio of 3.26 and a debt-to-equity ratio of 1.62. Phibro Animal Health Corp has a 52-week low of $32.02 and a 52-week high of $54.62. The company has a market cap of $1.33 billion, a price-to-earnings ratio of 19.06, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77.
Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.03). Phibro Animal Health had a return on equity of 38.91% and a net margin of 7.89%. The business had revenue of $200.20 million for the quarter, compared to analysts’ expectations of $203.99 million. During the same quarter in the prior year, the firm earned $0.38 earnings per share. Phibro Animal Health’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, research analysts predict that Phibro Animal Health Corp will post 1.72 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 19th. Stockholders of record on Wednesday, November 28th will be given a dividend of $0.12 per share. This is a boost from Phibro Animal Health’s previous quarterly dividend of $0.10. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.46%. The ex-dividend date is Tuesday, November 27th. Phibro Animal Health’s payout ratio is presently 27.59%.
Several research firms have issued reports on PAHC. BidaskClub downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. ValuEngine downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. Morgan Stanley boosted their price objective on shares of Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a research note on Wednesday, August 29th. Finally, Zacks Investment Research upgraded shares of Phibro Animal Health from a “sell” rating to a “buy” rating and set a $53.00 price objective for the company in a research note on Thursday, August 30th. Three research analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. Phibro Animal Health currently has an average rating of “Hold” and a consensus target price of $43.50.
Phibro Animal Health Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Featured Article: Conference Calls
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.